Is DIAGNOS Inc. (DGNOF) a Buy, Sell, or Hold?
OTC : DGNOF
DIAGNOS Inc. — News
$0.16 USD
-$0.01 (-5.88%)
- Volume
- 62.5K
- Average Volume
- 95.1K
- Market Capitalization
- $19.27M
- P/E Ratio
- -5.81
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.29
- Year Low
- $0.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.49
| Source | Headline |
|---|---|
|
DIAGNOS to Extend the Exercise Period of Stock Warrants
BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a "Warrant") from August 5, 2026 to June 5, 2027 (the "Amendment"). globenewswire.com - 2026-07-07 12:38:52 |
|
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
BROSSARD, Quebec, June 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that Emerging Growth Research today released a new flash report on DIAGNOS, highlighting the Company's progress toward key regulatory approvals and the growing commercialization opportunity for its CARA (Computer Assisted Retinal Analysis) artificial intelligence platform. globenewswire.com - 2026-06-05 10:00:00 |
|
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026
DIAGNOS invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. BROSSARD, Quebec, June 03, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that Mr. globenewswire.com - 2026-06-03 10:00:00 |
|
DIAGNOS Announces Amendment to Convertible Debentures
BROSSARD, Quebec, May 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to extend the maturity date of an aggregate amount of $300,000 of unsecured convertible debentures (each, a Debenture) issued as part of a non-brokered private placement of units initially announced on May 18, 2023, and subsequently amended on May 18, 2025 (pleaser refer to the press release dated May 20, 2025). The amended maturity date set for May 18, 2026, is extended to May 18, 2027 (the “Amendment”). globenewswire.com - 2026-05-13 19:00:00 |
